^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Prolymphocytic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/21/2023
    Excerpt:
    T-Cell Prolymphocytic Leukemia: SUGGESTED TREATMENT REGIMENS...Ruxolitinib…